NHS remove restrictions on ibrutinib for relapsed CLL

The Times recently reported that NHS England were not following NICE guidelines and were restricting funding of the targeted drug ibrutinib to people with chronic lymphocytic leukaemia (CLL) who relapsed (CLL got worse) within 3 years of previous treatment. This meant that people who had a long remission after their first treatment were unable to have ibrutinib on the NHS if they relapsed.